The Multifacets of COVID-19 in Adult Patients: A Concise Clinical Review on Pulmonary and Extrapulmonary Manifestations for Healthcare Physicians

Duran Canatan 1, Joan Lluis Vives Corrons 2, Vincenzo de Sanctis 3

1 Antalya Genetic Diseases Diagnostic Center, Antalya, Turkey, 2 Coordinator of the European Network for Rare and Congenital Anaemias (ENERCA). Erythropathology and Rare Anaemias Unit. Institute for Leukaemia Research Josep Carreras (IJC). Catalonia, Spain, 3 Coordinator of the International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine (ICET-A)

Summary. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people with COVID-19 have a mild to moderate respiratory illness; others experience severe illness, such as COVID-19 pneumonia. The first and most accessible diagnostic information is from symptoms and signs from clinical examination. Infected patients present with a variety of manifestations. Formal diagnosis requires laboratory analysis of nose and throat samples, or imaging tests like CT scans. Emerging data suggest that coronavirus disease 2019 (COVID-19) has extrapulmonary manifestations. Sometimes these extra-respiratory manifestations may be the initial or only symptom of COVID-19, prior to fever or respiratory manifestations. In summary, our concise review shows that there is a wide range of symptoms that can be presented by COVID-19 patients. Extra-respiratory manifestations of SARS-CoV-2 infection have recently been observed in the rapidly increasing number of COVID-19 cases. Considering the broad spectrum of clinical manifestations and the increasing worldwide burden of the disease, there is an urgent need to rapidly scale up the diagnostic capacity to detect COVID-19 and its complications. (www.actabiomedica.it)

Keywords: SARS-CoV-2 infection, COVID-19, signs and symptoms, extra-respiratory manifestations

Background

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global health threat, infecting 27, 150, 797 cases 1, 844, 863 people and resulting in 889, 256 deaths 117, 021 deaths at the time of the last writing (September 7th, 2020). This new type of respiratory illness is characterized by rapid human-to-human transmission, having achieved pandemic spread (1). There are currently no therapeutics or vaccines available and no pre-existing immunity in the population.

Because COVID-19 is a new disease, our awareness and knowledge are gradually increasing based on ongoing research findings and clinical practice experience. A significant amount of collective work has been done to understand the prevention and treatment strategies of COVID-19. The disease has posed unparalleled challenges for health care communities, the general population, and in particular, for patients suffering from chronic diseases (such as: thalassemia and sickle cell disease) (2).

A wealth of data has been generated since its emergence in December 2019, and it is vital for clinicians to keep up with this data from across the world at a time of uncertainty and constantly evolving guidelines and clinical practice. Increasing knowledge about COVID-19 literature will aid in earlier recognition and more effective therapy.

Here, we provide a brief overview of recent knowledge, mainly focused on extrapulmonary manifestations reported in the literature in adult patients.
Search strategy

A systematic English-language literature search was carried out, from 1 January 2019 to 31 August 2020, using the main online databases (PubMed, Google Scholar, and MEDLINE) with the following keywords: ‘COVID-19’, ‘2019-nCoV’, ‘coronavirus’ and extrapulmonary manifestations. In addition, the references contained in the downloaded documents were examined for other sources of information that would be pertinent to our review. The literature search was updated until September 2020.

Structure of SARS-CoV-2

SARS-CoV-2 is an enveloped, positive-sense single-stranded RNA virus, from beta-coronavirus genera of *coronaviridae* family responsible for the 2019 coronavirus disease (COVID-19) pandemic. SARS-CoV-2 contains 29891 nucleotides encoding 9889 amino acids and four structural proteins, namely spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of which S protein mediates the viral entry into host cells (Figure 1). The spikes (S) and the nucleocapsid (N) are the main proteins (antigens) which trigger an antibody response in humans. SARS-CoV-2 also contains a variable number of open reading frames (ORF), and these encode 16 non-structural proteins, the remaining ORFs encode structural proteins (3-5).

SARS-CoV-2 and influenza primarily affect the respiratory system. SARS-CoV-2 gains access to the host cells using its surface spike (S) protein to bind human angiotensin-converting enzyme 2 receptor on host cells. The viral entry triggers a host immune response with a massive release of cytokines thought to be responsible for organ dysfunctions (6).

Pathophysiology

The pathogenesis of COVID-19 is largely unknown, but it may mimic SARS to some extent. SARS-CoV-2 attacks the alveolar epithelial cells via angiotensin-converting enzyme 2 (ACE2) via S-protein. ACE-2 is found on apical membranes of nasal, oral, nasopharyngeal and oropharyngeal mucosal epithelium, alveolar epithelium, endothelial cells of blood vessels and heart, kidneys, testes, brain, intestine, and colon (7,8).

ACE-2 has been proven to be a major receptor for SARS-CoV-2 and could mediate virus entry into cells. And transmembrane protease serine 2 (TMPRSS2) could cleave the spike (S) protein of SARS-CoV-2, which facilitates the fusion of SARS-CoV-2 and cellular membranes. The mRNA expressions of both ACE2 and TMPRSS2 were observed in the heart, digestive tract, liver, kidney, brain and other organs. SARS-CoV-2 may have a capacity to infect extrapulmonary organs due to the expressions of ACE2 and TMPRSS2 in the cells and tissues of these organs (9) (Figure 1).

Spike proteins on the exterior of SARS-CoV-2 anchor the virus to ACE-2 receptors on cells in the lower respiratory tract leading to endothelial and microvascular dysfunction, alveolar exudative inflammation, interstitial inflammation and fibrosis, and focal bleeding which causes severe respiratory manifestation of the disease (7).

ACE-2 is a counter-regulatory enzyme of renin-angiotensin-system which acts by converting angiotensin-2 to Ang-1–7 form. In healthy state, ACE-2 activity maintains homeostasis between angiotensin-2 (vasoconstriction, inflammation, fibrosis and proliferation) and Ang-1–7 pathways (vasodilatation, anti-apoptotic, anti-fibrosis, and anti-proliferation). After entering pneumocytes, SARS-CoV-2 downregulates ACE-2 expression, decreasing angiotensin-2 metabolism. Elevated angiotensin-2 increases pulmonary vascular permeability and inflammation, hence worsening of lung injur. Angiotensin-2 levels have been found to be increased in COVID-19 patients compared to healthy adults (7–9).

Routes of transmission and period of incubation

The disease is said to be transmitted through droplets from human saliva, eyes, and nose. A recent study found that SARS-CoV-2 lasts in aerosols for up to 3 hours and remains detectable for up to 72 hours...
on plastic and stainless-steel surfaces, 24 hours on cardboard, and 4 hours on copper. Fecal-oral transmission may also be possible but has not been verified to be clinically important (10,11).

Individuals of any age are susceptible to infection, including neonates and pregnant women.

The mean incubation period of SARS-CoV-2 is estimated to be 3–7 days (range, 2–14 days) (12).

This period is dependent on the age of the patient and status of the patient’s immune system. It was shorter among patients >70–years old compared with those under the age of 70 years. Figure 2 illustrates the immune response to viral infection. The SARS-CoV-2 virus persists in fecal samples for an average of 27 days, which is 10 days longer than its persistence in respiratory tract samples (13).

**Figure 1.** Structure of SARS-CoV-2. (A) There are four structural proteins as follows: spike (S) surface glycoprotein; membrane (M) protein; nucleocapsid (N) protein and envelope (E) protein. SARS-CoV-2 infected the host cells by the spike protein of the virus and the functions of ACE2 and TMPRSS2 in host cells.

**Figure 2.** The immune response to viral infection [From: WHO. COVID-19 immunity and clinical manifestations. CORONAVIRUS (COVID-19) UPDATE NO. 24. May 1st, 2020]
Clinical features and Risk factors

It has been proposed that COVID-19 progresses through several stages in its disease course. The first stage is viral infection during which constitutional symptoms, such as fever and cough, predominate. The second stage is characterized by direct viral cytotoxic effects, particular those in the respiratory tract, leading to respiratory failure and potentially acute respiratory distress syndrome. The third and final stage is thought to be mediated by a hyperinflammatory response to the virus causing systemic effects (14).

The symptoms of SARS-CoV-2 infection seem to be non-specific, as far as clinical manifestations are being concerned. They may be very similar to influenza (Table 1). Gastrointestinal symptoms such as nausea and vomiting (5%) and diarrhoea (3.8%) are relatively uncommon (10,12).

The symptoms of COVID-19 initially begin with symptoms of fatigue, low-grade intermittent fever of prolonged duration, myalgia, dry cough and shortness of breath, which then either improves with early identification and conservative management or worsens and progresses to dyspnoea and productive cough. The median duration of fever was 12 days (8–13 days) and cough persisted for 19 days (12–23 days) in survivors. The median time to onset of dyspnoea from various cohorts was found to be 6 days following exposure. Serious cases can progress rapidly into acute respiratory distress syndrome (ARDS), septic shock, refractory metabolic acidosis, coagulation dysfunction and others such as acute kidney injury (AKI), acute cardiac injury (arrhythmias, heart failure, MI) (15,16). Complications developed at a median of 9-17 days.

Given the wide clinical spectrum of COVID-19, a key challenge faced by frontline clinical staff is prioritisation of stretched resources. The clinical criteria for assessing the severity of COVID-19 are reported in Table 2. Furthermore, several evidences suggest that severe disease is more likely to take hold in individuals of older age, male sex, and in those with underlying co-morbidities, such as: diabetes, chronic obstructive pulmonary disease (COPD), hypertension, obesity (17).

To explore the clinical and laboratory risk factors associated with disease severity, an univariate and multivariate logistic regression models was used by Liu et al. (18). In the univariate analysis, hypertension, leucopenia, elevated neutrophil count, lactate dehydrogenase (LDH), C-reactive protein (CRP), and symptoms such as dyspnea, fatigue, and anorexia/lethargy were all associated with severe cases. In the multivariable logistic regression model, the Authors included 90 patients (56 pneumonia and 34 severe pneumonia). Hypertension, increased CRP and lymphocyte count as independent were identified as predictors of severe pneumonia.

Relationship between the ABO Blood Group and the COVID-19 Susceptibility published.

Table 2. Criteria for assessing the severity of COVID-19

| Severity          | Criteria                                                                 |
|-------------------|--------------------------------------------------------------------------|
| Mild              | Minimal symptoms without pulmonary involvement in chest imaging studies |
| Moderate          | Fever and/or respiratory symptoms; multiple limited patchy shadows and intermittent changes in chest imaging |
| Severe            | Dyspnoea with a respiratory rate of >30 breaths per minute; resting oxygen saturation below 95% or arterial blood oxygen partial pressure/oxygen concentration ≤300 mmHg (1 mmHg=0.133 kPa); multiglobular disease or lesion progression of >50% within 48 h; sequential organ failure assessment (SOFA) of ≥2 points; pneumonia and/or other clinical conditions requiring hospitalization |
| Critically ill    | Respiratory failure requiring mechanical ventilation; septic shock; additional organ failure |

Table 1. Common signs and symptoms of SARS-CoV-2 infected patients from four reports (From: Zheng J et al. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. Int J Biol Sci. 2020;16:1678-1685, modified)
Blood group A was associated with a higher risk for acquiring COVID-19 compared with non-A blood groups, whereas blood group O was associated with a lower risk for the infection compared with non-O blood groups (19).

**Laboratorial findings**

Lymphopenia is a common finding in patients with COVID-19 infection, and is believed to represent a defective immune response to the virus (20).

Leukocytosis, is noted in a minority of COVID-19 infected patients and appears to herald bacterial infection or superinfection while neutrophilia is an expression of the cytokine storm and hyperinflammatory state which have an important pathogenetic role in COVID-19. Neutrophilia may also indicate superimposed bacterial infection (20). Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases (20,21).

Thrombocytopenia is an important indicator of severe disease in COVID-19 patients as well as D-dimer increases and progressive decrease of lymphocytes in peripheral blood. In quite a few patients, increase of liver enzymes, muscle enzymes, and myoglobin are observed (20,21).

Association of Autoimmune Haemolytic Anaemia (AHA) with COVID-19 infection has been rarely reported (22).

On initial presentation a majority of COVID-19 patients have procalcitonin levels in the normal range (20,22). Elevated procalcitonin levels may be seen in sepsis and are particularly associated with septic shock and organ dysfunction requiring intervention. Prothrombin time (PT), an assay used to evaluate the extrinsic and common coagulation pathways, and D-dimer are useful indicators of prognosis and severity of disease in COVID-19 (22).

Severely ill patients may have high levels of cytokine IL6 (>7.4 pg/mL), and tumor necrosis factor (TNF). Increased ferritin level (>300 μg/L) is an indicator of the imminent cytokine storm (20,21).

Early recognition of these parameters may be useful to predict the disease severity, to guide the therapy, and improve the patients’ clinical outcome (Table 3).

The three complete blood count findings of poor prognosis are: leukocytosis, thrombocytopenia, and lymphocytopenia. Whether poor prognosis is associated with lymphocytopenia below the reference interval or absolute count is unclear.

### Table 3. Hematologic and laboratory findings in patients with mild/moderate SARS-CoV-2 infection

| Parameter                               | Clinical significance                              | Mild/moderate cases (%) |
|-----------------------------------------|---------------------------------------------------|-------------------------|
| Lymphopenia (<1.5 × 10^9/L)             | Defective host response                           | 47-54%                  |
| Leukocytosis (>10×10^9/L)               | Bacteria superinfection                           | 19–30%                  |
| Neutrophilia                            | Bacterial superinfection, cytokine storm          | 1.4%                    |
| Thrombocytopenia (>100 × 10^9/L)       | Consumptive coagulopathy                         | 4%                      |
| Elevated CRP                           | Severe viral infection, including viremia         | 45.5-56.4%              |
| Elevated procalcitonin (≥0.25 to <0.5 ng/mL) | Bacterial superinfection                       | 7%                      |
| Elevated LDH (>245 U/L)                | Pulmonary injury/ multiorgan damage               | 63%                     |
| Prolonged prothrombin time (>16 s)     | Consumptive coagulopathy                         | 1.7%                    |
| Prolonged APTT (>37.0 s)               | Consumptive coagulopathy                         | 9.6%                    |
| Elevated D-dimer (>1 μg/L) and/or FDP  | Consumptive coagulopathy                         | 6%                      |

*Legend: Abbreviations = CRP - C reactive protein; LDH – lactate dehydrogenase; APTT-activated partial thromboplastin time; FDP- fibrin degradation product.*
Differential diagnosis

On the basis of currently available data, neither absence nor presence of signs or symptoms are accurate enough to rule in or rule out COVID-19 disease. Signs of SARS-CoV-2 infection overlap with other viral infections (viral respiratory illnesses, respiratory syncytial virus, influenza, parainfluenza, adenovirus, and metapneumovirus) and bacterial pneumonia (streptococci, mycoplasma, chlamydia, legionella) that makes the clinical and radiological diagnosis very tricky (9, 12,15). Therefore, in the current epidemic time, when we face an inpatient with fever and/or new onset cough, with or without associated dyspnoea, all efforts should be directed at ruling out aetiologies other than SARS-CoV-2 through history, physical examination and routine laboratory tests. In Table 4 is reported the frequency of symptoms in COVID-19, flu and common cold.

Influenza globally affects 5-10% of adults and 20-30% of children annually with most cases occurring during the winter months in the northern (November to April) and southern hemispheres (April to September) with no seasonal pattern in the tropical regions (23,24). Influenza-related respiratory diseases are responsible annually for an estimated 650,000 deaths globally (25).

Table 4. Frequency of symptoms in COVID-19, flu and common cold [From: WHO. COVID-19 immunity and clinical manifestations. CORONAVIRUS (COVID-19) UPDATE NO. 24. May 1st, 2020]

| SYMPTOMS          | COVID-19 | FLU      | COMMON COLD |
|-------------------|----------|----------|-------------|
| Fever             | Common   | Common   | Rare        |
| Dry Cough         | Common   | Less common | Less common |
| Tiredness         | Common   | Less Common | Common     |
| Shortness of breath | Less common | Less Common | Rare        |
| Aches and pains   | Less common | Common   | Rare        |
| Headache          | Less common | Common   | Rare        |
| Sore throat       | Less common | Less common | Common     |
| Diarrhea          | Less common | Less common | Rare        |
| Stuffy nose       | Rare     | Less common | Common     |
| Runny nose        | Rare     | Common   | Common      |
| Sneezing          | Rare     | Rare     | Common      |
patient to less radiation and is more widespread than CT scan (30,31).

Chest CT is highly recommended as the preferred imaging diagnosis method for COVID-19 due to its high density and high spatial resolution. The common CT manifestation of COVID-19 includes multiple segmental ground glass opacities (GGOs) distributed dominantly in extrapulmonary/ subpleural zones and along broncho-vascular bundles with crazy paving sign and interlobular septal thickening and consolidation. Pleural effusion or mediastinal lymphadenopathy is rarely seen (17,32,33).

Other viral pneumonia manifest generally diffuse large patches of GGOs in both lungs with thickening of interlobular septum, which makes it hard to differentiate them from COVID-19 pneumonia in images and clinically. COVID-19 ground-glass opacities are usually peripherally located with the lower lobes being commonly involved, while influenza has a central, peripheral, or random distribution usually affecting the five lobes (17,34) (Table 5).

Ultrasonography (US) has been employed in the detection of interstitial disorders, consolidation, and effusions (35). US is also a useful tool to support the ventilated patient in terms of assessing diaphragm mobility and supporting recruitment maneuvers (36).

### Extrapulmonary manifestations

Although COVID-19 is well known to cause respiratory pathology, it can also result in several extrapulmonary manifestations of gastrointestinal system, cardiovascular system, liver, and kidneys (Figure 3). Key mechanisms that may have a role in the pathophysiology of multi-organ injury secondary to SARS-CoV-2

![Extrapulmonary manifestations of COVID-19](From: Aakriti Gupta et al. Nature Medicine. 2020;26:1017–1032; www.nature.com/naturemedicine, modified)

| Diseases                | High-risk groups                  | CT imaging findings                                                                 |
|-------------------------|-----------------------------------|-------------------------------------------------------------------------------------|
| COVID-19                | Elderly people; People with comorbidities | **Early stage:** GGOs, Progressive stage: multiple GGOs, consolidation patches, crazy-pavement pattern  |
|                         |                                   | **Advanced stage:** diffuse exudative lesions, white-out lung                        |
| Influenza pneumonia     | Elderly people; Children under 5 years old | Small patch GGOs and consolidation with subpleural and or peribronchial distribution. Bilateral reticulonodular areas of opacity. |
| Mycoplasmal pneumonia   | Children, adolescents and young adults | Interstitial infiltration or consolidations of segments or lobes manifested by patchy or fan-shaped infiltration.  |
|                         |                                   | Thickening of the bronchial wall, centrilobular nodules, consolidations distributed along lobes, segments or subsegments of the lung, and enlargement of mediastinal lymph nodes. |
| Bacterial pneumonia     | All ages                          | Bronchial or lobar pneumonia, bronchial wall thickening, multiple consolidation patches and centrilobular nodules |

*Table 5. Imaging characteristics of common causes of pneumonia similar to COVID-19 pneumonia* (From: Li B et al. Diagnostic value and key features of computed tomography in Coronavirus Disease 2019. Emerg Microbes Infect. 2020;9:787-793; modified)

*Legend: GGO: ground-glass opacity.*
infection include direct viral toxicity, endothelial cell damage and thromboinflammation, deregulation of the immune response, and deregulation of the renin–angiotensin–aldosterone system (RAAS) (37,38).

1. Dermatologic manifestations

Skin manifestations are seen in up to 20% of COVID-19 patients and are very heterogeneous. To date, reports have identified 5 main category of skin manifestations: acral lesions, vesicular rashes, urticarial rashes, maculopapular rashes, and livedoid and necrotic lesions. The presentation may vary in different population groups and are based on severity of disease.

The predominant places of dermatologic manifestations are the torso and body’s extremities and the latency period of the cutaneous symptoms vary from 1 to 30 days. However, some of them may emerge before the onset of COVID manifestations. The lesions’ progressive disappearance vary from four days to three weeks (39-41).

Cutaneous manifestations associated with COVID-19 probably reflect the activation of pathogenic pathways by the virus or a response to inflammatory processes, vascular or systemic complications, or even treatments (39-41).

A severe multisystem inflammatory syndrome associated with Kawasaki disease manifestations (MIS-C) has been recently reported in children with signs of recent infection with SARS-CoV-2. However, clinicians caring for adult patients must be aware that not only children but also young adults can be affected by a multisystem inflammatory syndrome with Kawasaki’s disease features associated with COVID-19 (42).

2. Cardiovascular manifestations

COVID-19 can be complicated by cardiac arrhythmias or clinical heart failure with or without associated hemodynamic instability, including shock (43). These cardiac complications can occur precipitously at any point during hospitalization and are increasingly being described as a late complication that can occur after improvements in a patient’s respiratory status (44,45).

The cardiac manifestations of COVID-19 might be related to the adrenergic drive, systemic inflammatory milieu and cytokine-release syndrome caused by SARS-CoV-2, direct viral infection of myocardial and endothelial cells, hypoxia due to respiratory failure, electrolytic imbalances, fluid overload, and side effects of certain COVID-19 medications (46).

Monitoring may include serial cardiac troponin and natriuretic peptides, along with fibrinogen, D-dimer, and inflammatory biomarkers. Management of acute COVID-19 cardiovascular syndrome should involve a multidisciplinary team including intensive care specialists, infectious disease specialists, and cardiologists.

3. Venous thromboembolic events (VTEs)

Patients with moderate and severe COVID-19 illness are more likely to have a hypercoagulable state placing them at high risk for venous thromboembolism (VTE) (47,48). VTE occurs approximately in 25% of severe COVID-19 patients (47).

Careful evaluation of laboratory indices at baseline and during the disease course (platelet count, PT, fibrinogen, D-dimer, antithrombin and protein C activity monitoring) can assist clinicians in formulating a tailored treatment approach and promptly provide intensive care to those who are in greater need (48).

Prophylactic low-molecular-weight heparin (LMWH) has been recommended by the International Society on Thrombosis and Haemostasis (ISTH) and the American Society of Hematology (ASH), but the best effective dosage is uncertain. As per recommendations by the American College of Chest Physicians, in the absence of contraindications, thrombotic prophylaxis is recommended in all moderate and severe COVID-19 patients, while low molecular weight heparin (LMWH) is preferred to oral anticoagulants (49). In patients requiring ICU admission, therapeutic treatment of LMWH can be effective in reducing in-hospital mortality.
4. Gastrointestinal (GI) and hepatic manifestations

The most common GI symptoms reported are diarrhea, nausea, vomiting, and abdominal discomfort, and few COVID-19 case reports have been reporting cases with GI symptoms preceding respiratory symptoms, with some patients only presenting with digestive symptoms in the absence of respiratory symptoms (50-52). Therefore, these uncommon GI presentation presentations can potentially lead to delay in diagnosis of COVID-19 (53).

SARS-CoV-2 infects the GI tract via its viral receptor angiotensin converting enzyme II, which is expressed on enterocytes of the ileum and colon.

An increasing number of COVID-19 patients experience hepatic injury, ranging on a spectrum of mild to severe damage. Most liver injuries are mild and transient, but severe liver damage can also occur in patients with severe COVID-19 and is associated with negative outcomes (54). Patients with chronic liver diseases, especially in those with pre-existing cirrhosis, there is an increased risk of worse outcomes in COVID-19, that have been attributed to their immunocompromised status (55).

The definitive mechanism by which liver injury occurs in COVID-19 patients is unclear. Liver injury in patients with COVID-19 might be due to viral infection in liver cells or due to other causes such as drug induced liver injury and systemic inflammation induced by cytokine storm or pneumonia-associated hypoxia. Furthermore, drug-induced hepatotoxicity may play a role in the elevation of liver enzymes, including medications such as remdesivir (an RNA polymerase inhibitor) and hydroxychloroquine (56).

5. Pancreas injury

In a recent study by Wang et al. (57) examining 52 patients with COVID-19 pneumonia, 17 % of patients experienced pancreatic injury, documented by an increase of amylase or lipase serum levels, in absence of clinical symptoms of pancreatitis. Mechanisms by which pancreatic injury could occur include the direct cytopathic effects of SARS-CoV-2, or indirect systemic inflammatory and immune-mediated cellular responses, resulting in organ damage or secondary enzyme abnormalities. The ACE2 receptor is also highly expressed in pancreatic islet cells, therefore SARS-CoV-2 infection can theoretically cause islet damage resulting in acute diabetes (58).

6. Neurological manifestations

According to several studies, more than 35% of COVID-19 patients develop neurological symptoms sometimes as the initial presentations of the disease.

The neurological manifestations and complications of COVID-19 can be divided into central (encephalopathy, acute hemorrhagic necrotizing encephalopathy, acute myelitis, cerebrovascular accident, encephalitis, headaches and dizziness), and peripheral (anosmia and chemosensory dysfunction, Guillain Barré syndrome, skeletal muscle damage) (59,60).

It is still unclear if these complications are directly due to the viral infestation or post-infectious auto-immune reactions, or hypoxic metabolic changes (59,60). Furthermore the hyperactivation of inflammatory factors may disrupt the coagulation system leading to D-dimer and platelet abnormalities, that may provoke the occurrence of cerebrovascular diseases (CVD) such as acute ischemic stroke (61).

6.1. Central nervous system (CNS) manifestations

The most common central nervous system (CNS) symptoms are dizziness (16.8%) and headache (13.1%), other less frequent symptoms included impaired consciousness (7.5%), acute cerebrovascular disease (2.8%), ataxia (0.5%), seizure (0.5%), vision impairment (1.4%) and nerve pain (2.7%). Headache, myalgia, and malaise are common initial neurological symptoms. Altered sensorium, in severe COVID-19, ranges from confusion, delirium, stupor to coma (59,60). The prevalence of neurological signs and symptoms is higher in patients with severe COVID-19 infection, which may be the result of cerebral hypoxia due to respiratory failure (59,60).
6.2. Peripheral nervous system (PNS) manifestations

PNS sign and symptoms of COVID-19 include hyposmia/anosmia, hypogeusia/ageusia, muscle pain, and Guillain-Barre syndrome (GBS). Spinal cord involvement is uncommon (62).

Anosmia and/or ageusia are the most common PNS manifestations of SARS-COV-2. In a multicenter European study among 417 mild-to-moderate COVID-19 patients, 85.6% and 88.0% of patients had olfactory and/or gustatory dysfunctions, respectively. Women were more likely to be affected, and there was an early olfactory recovery rate of 44%, while symptoms could last even 14 days after the resolution of symptoms (63). These symptoms occur suddenly, and usually with fewer nasal symptoms such as nasal obstruction or excessive nasal secretion. Anosmia and ageusia are mostly present in asymptomatic individuals or as the initial presentation of the disease with no other symptoms.

7. Ocular manifestations

Coronaviruses may induce a wide spectrum of ophthalmic manifestations, such as conjunctivitis, anterior uveitis, retinitis, or optic neuritis (64-67). The prevalence of ocular manifestations varies from 2% to 32% (67) and is associated with the severity of the COVID-19 (64-66).

Similarly, to other symptoms not related to the respiratory system, ophthalmic manifestations might appear as the first symptom without any other impairments.

Several mechanisms for the ocular transmission of the virus are proposed with highlight on the nasolacrimal system as a conduit between the eye and the respiratory tract, and the role of the lacrimal gland in hematogenous spread. However, it is likely that the virus does possess an ocular tropism, as do other respiratory viruses. Furthermore, given the high vascularity of conjunctiva, along with the expression of ACE2 on the surface of endothelial cells, it cannot be excluded that the ocular manifestation of SARS-CoV-2 infection may in fact manifest in the form of a local, transient vasculitis (68,69).

8. Renal manifestations

The kidneys are one of the most frequently affected extrapulmonary organs in patients infected with SARS-CoV-2; especially, in those patients who are severely ill (70). Hematuria has been reported in nearly half of patients with COVID-19, and proteinuria has been reported in up to 87% of critically ill patients with COVID-19. The occurrence of acute kidney injury (AKI) among patients with COVID-19 is not consistent across published studies, ranging from 0.1% to 29% (70-74). Recently, Sun et al (75) have reported the occurrence of subclinical AKI as reflected by increased urinary levels of β2-microglobulin, α1-microglobulin, N-acetyl-β-D-glucosaminidase, and retinol-binding protein (ie, all biomarkers of kidney tubular damage) in a sample of 32 confirmed COVID-19 cases without prior chronic kidney disease.

Although the mechanisms for the renal manifestations of COVID-19 are still elusive, a complex multifactorial pathway has been proposed and it includes: (a) direct viral involvement and replication in the kidneys leading to dysfunction; (b) local disruption in renin–angiotensin–aldosterone system (RAAS) homeostasis, and (c) as a result of a systemic inflammatory response “cytokine storm” (70,71,76).

Monitoring of markers of kidney function could help in the identification of patients who are at high risk for worse outcomes (76). However, more work is needed to help us better understand the pathophysiology underlying renal manifestations of COVID-19, to help in the identification of effective management strategies.

9. Reproductive health issues

A recent study using single-cell RNA sequencing found that the ACE2 receptor, a target for SARS-CoV-2 infection, is expressed in germ cells, Leydig cells, and Sertoli cells in the testis (77), suggesting the testis is potentially a tropism site and reservoir for the SARS-CoV-2 virus. Sertoli cells play a critical role in the homeostasis of seminiferous tubules and spermatogenesis and Leydig cells are involved in androgen production.
It has been reported that semen analysis following COVID-19 infection showed a low sperm concentration with low motility for up to three months post-infection (78). This might indicate that the effect of COVID-19 on male fertility might be only transient. Furthermore, a study conducted on 81 male patients with COVID-19 showed low testosterone level, high luteinizing hormone (LH) level and low testosterone/LH ratio indicating a possible viral testicular damage which subsequently affects the function of Leydig cells (79). Therefore, it has been suggested that the male survivors of COVID-19, especially those with reproductive needs, should be examined for testicular function and reproductive function after recovery (80).

An unusual presentation of a male case with severe external genital pain which was suspected to be the first clinical sign of COVID-19. has been reported by Özveri et a. (81)

In conclusion

COVID-19 probably represents the greatest pandemic event in modern human history. Our concise review shows that the disease presents a broad spectrum of clinical signs and symptoms. Extra-respiratory manifestations of SARS-CoV-2 infection have recently been observed in the rapidly increasing number of COVID-19 cases involving of vital organs such as: lungs, heart, gastrointestinal tract, liver, kidneys, central and peripheral system, and blood.

The main mechanism described is the high binding affinity of the virus with the ACE2 receptors that are widely expressed in most human cells.

Commonly, multisystemic involvement is associated with severe disease and might predict worse clinical outcomes and increased mortality. Therefore, a prompt high vigilance among primary care and emergency doctors is very important. Delineating the whole spectrum of symptoms of the disease can help with early diagnosis, prevention of the spread of the disease, and its treatment. In addition, it can help with the prevention of complications that may arise in the long term.

Acknowledgement

This project is supported and Co-Funded by the Erasmus and Programme of the European Union.

Project Title

Hemoglobinopathies for Immigrants. Education, Prevention ,Genetic Diagnosis and Treatment Approach.

Declaration of interest

The authors report no conflicts of interest.

References

1. European Centre for Disease Prevention and Control. COVID-19 situation update worldwide, as of 7 September 2020. https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases.
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;10.1001/jama.2020.2648. doi:10.1001/jama.2020.2648.
3. Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharyya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. GeroScience. 2020;42:505–514.
4. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;10.1002/jmv.26234. doi:10.1002/jmv.26234.
5. Canatan D, De Sanctis V. The impact of MicroRNAs (miRNAs) on the genotype of coronaviruses. Acta Biomed. 2020;91:195–198.
6. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV-2 a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7:226–236.

7. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097–1100.

8. Di Gennaro F, Pizzol D, Marotta C, et al. Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. Int J Environ Res Public Health. 2020;17(8):2690. Published 2020 Apr 14. doi:10.3390/ijerph17082690.

9. Dong M, Zhang J, Ma X et al. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed Pharmacother. 2020 Aug 4;131:110678. doi: 10.1016/j.biopha.2020.110678.

10. Xiao F, Tang M, Zheng X. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158:1831–1833.

11. Wang W, Xu Y, Gao R. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843–1844.

12. Yang Y, Lu Q, Liu M, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv. 2020. https://doi.org/10.1101/2020.02.03.20014605.

13. Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. doi:10.1016/S2468-1253(20)30083-2.

14. Atri D, Siddiqi HK, Lang J. COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC Basic Transl Sci. 2020;5:518–536.

15. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020;7(7): CD013665. doi:10.1002/14651858.CD013665.

16. Zheng Q, Lu Y, Lure F, Jaeger S, Lu P. Clinical and radiological features of novel coronavirus pneumonia. J Xray Sci Technol. 2020;28:391–404.

17. Han W, Quan B, Guo Y, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. 2020;92:461–463.

18. Liu X, Zhou H, Zhou Y, et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. J Infect. 2020;81:e95–e97.

19. Zhao J, Yang Y, Huang H et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility Clin Infect Dis. 2020 Aug 4;ciaa1150. doi:10.1093/cid/ciaa1150.

20. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020;58:1070–1076.

21. Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol. 2020;42 Suppl 1:11–18.
risk of different human organs vulnerable to 2019-ncov infection. Front Med. 2020;14:185–192.
38. Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol. 2020;318:F1454-F1462.
39. Galván Casas C, Catalá A, Carretero Hernández G. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020 Apr 29:10.1111/bjd.19163. doi: 10.1111/bjd.19163.
40. Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on feet and hands during the COVID-19 Pandemic. Int J Dermatol. 2020;59:739–743.
41. Tang K, Wang Y, Zhang H, Zheng Q, Fang R, Sun Q. Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): A brief review. Dermatol Ther. 2020;13:1528. doi:10.1111/dth.13528.
42. Cogan E, Foulon F, Cappeliez O, Dolle N, Vanfraechem G, De Backer D. Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report. Front Med (Lausanne). 2020;7:428. Published 2020 Jul 14. doi:10.3389/fmed.2020.00428.
43. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069.
44. Fried JA, Ramasubbu K, Bhart R, et al. The variety of cardiovascular presentations of COVID-19 [published online April 3, 2020]. Circulation. doi: 10.1161/CIRCULATIONNAHA.120.047164.
45. Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. A current review of COVID-19 for the cardiovascular specialist. Am Heart J. 2020;226:29–44.
46. Boukhris M, Hillani A, Moroni F, et al. Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective. Can J Cardiol. 2020;36:1068–1080.
47. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421–1424.
48. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–847.
49. Moores LK, Tritescher T, Brosnahan S, et al. Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST guideline and expert panel report. Chest. 2020;3692:31625–31621.
50. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020, 51:843–851.
51. Huang C, Wang Y, Li X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
52. Tran J, Glavis-Bloom J, Bryan T, Harding KT, Chahine C, Houyshar R. COVID-19 patient presenting with initial gastrointestinal symptoms. Eurorad. 2020;Case 16654.
67. Ulhaq ZS, Soraya GV. The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid. Graefe’s Arch Clin Exp Ophthalmol. 2020;258:1351–1352.

68. Ho D, Low R, Tong L, Gupta V, Veeraraghavan A, Agrawal R. COVID-19 and the Ocular Surface: A Review of Transmission and Manifestations. Ocul Immunol Inflamm. 2020;28:726–734.

69. Jiang G, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170:1136–1147.

70. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020;1–9. doi:10.1080/07853890.2020.1790643.

71. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98:209–218.

72. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763–1770.

73. Farouk SS, Fiaccadori E, Cravedi P, Campbell KN. COVID-19 and the kidney: what we think we know so far and what we don’t. J Nephrol. 2020;1–6. doi:10.1007/s40620-020-00789-y.

74. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020;1–9. doi:10.1080/07853890.2020.1790643.

75. Sun DQ, Wang TY, Zheng KI, et al. Subclinical acute kidney injury in COVID-19 patients: a retrospective cohort study. Nephron. 2020;1–4. https://doi.org/10.1159/000508502.

76. Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. 2020:2020.03.04.20031120.

77. Shen Q, Xiao X, Aierken A, et al. The ACE2 expression in Sertoli cells and germ cells may cause male reproductive disorder after SARS-CoV-2 infection [published online ahead of print, 2020 Jun 28]. J Cell Mol Med. 2020;24:9472–9477.

78. Wang Z, Xu X. scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in Spermatogonia, Leydig and Sertoli cells. Cells 2020;9(4):920.

79. Ma L, Xie W, Li D. Effect of SARS-CoV-2 infection upon male gonadal function: a single center-based study. medRxiv. 2020 doi: 10.1101/2020.03.21.20037267.

80. Chen F. Rising Concern on Damaged Testis of COVID-19 Patients. Urology. 2020;142: 42. doi: 10.1016/j.urology.2020.04.069.

Received: 19 September 2020
Accepted: 21 September 2020
Correspondence:
Vincenzo De Sanctis, MD
Coordinator of the International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine (ICET-A)
Via Paolo V, 25
44121 Ferrara (Italy)
E-mail:vdesanctis@libero.it